Aclaris Therapeutics, Inc. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aclaris Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2017-09-30 was -$12.00K.
- Aclaris Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2017-06-30 was -$5.00K.
- Aclaris Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2017-03-31 was $185.00K.
- Aclaris Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2016 was $4.00K.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2017-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | |
| 2017-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | |
| 2017-03-31 | $185.00K 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $4.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |